New hope for tough myeloma: experimental drug SG2918 enters human trials

NCT ID NCT07454187

Recruiting now Disease control Sponsor: Hangzhou Sumgen Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SG2918 in 40 people with relapsed or refractory multiple myeloma, a type of blood cancer that has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and how well the body tolerates it, with early signs of effectiveness also being measured. Participants receive SG2918 by intravenous infusion every three weeks at different dose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SG2918 (an experimental drug given by intravenous infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
The First Affiliated Hospital Of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China
The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital)
RECRUITING

Xi’an, Shanxi, 710000, China
The Second Affiliated Hospital Zhejiang University School Of Medicine
RECRUITING

Hangzhou, Zhejiang, 310056, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.